News | May 08, 2025
Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This significant milestone enhances our global regulatory standing
The Q1 2025 also witnessed a successful launch of Allegra D
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Subscribe To Our Newsletter & Stay Updated
